Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M6620 in Advanced Solid Tumors
NCT03718091Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of berzosertib in solid tumor, leiomyosarcoma (LMS), osteosarcoma (OS) and 1 more (12 cohorts), sponsored by Massachusetts General Hospital. Primary endpoints: Changes in Phospho-Chk1 Levels in Biopsy Specimens at Day 15, Change in yH2AX Levels in Biopsy Specimens at Day 15 and 1 more. Started Jan 2019; status: completed.
02
Drugs
berzosertib
03
Conditions
solid tumorleiomyosarcoma (LMS)osteosarcoma (OS)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT03718091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03718091.